GnosisDAO has approved a plan to retire Gnosis Chain's standalone Layer 1, unlocking approximately 350000 GNO, which is about 27% of the token's circulating supply. Under GIP-153, Gnosis Chain will transition to a zero-knowledge-proven Ethereum Economic Zone rollup, settling directly to Ethereum every block. This change will eliminate the independent validator set and rely on Ethereum validators for security. The approval is a direction-level mandate, with the first EEZ version expected around December 2026 or January 2027, pending infrastructure readiness. GNO rose 10% to about 136 around the governance decision, reflecting investor interest in Gnosis' integration with Ethereum. The transition will require Gnosis to rethink GNO's economics, as staking will end. Currently, validator rewards are paid from the treasury, with GIP-153 estimating a 2.3% annual dilution for non-stakers. After the validator set is retired, Gnosis plans to link GNO to revenue generated by the rollup, with options like fee sharing or GNO buybacks under consideration. The goal is to provide applications direct access to Ethereum's liquidity without bridging assets. Several DeFi projects have committed to building products in this new environment. However, the transition may lead to a less decentralized execution layer, as Gnosis Ltd. is expected to operate the sequencer for transaction ordering and block production.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.







Expanded U.S. Treasury long-bond buybacks helped pull yields lower and supported a modest rebound in risk appetite, with the major indexes closing slightly higher. At the same time, Bitcoin briefly rose above $70,000 and lifted crypto-linked equities, while positive Phase 3 vaccine data from Merck and Moderna pushed healthcare and biotech stocks higher. SK Hynix’s large-scale buyback also kept attention on the storage cycle and AI-related demand. Markets are continuing to digest the relatively hawkish Fed minutes while positioning ahead of earnings from Alibaba and Walmart.



Bitcoin and Ethereum surged in a historic 24-hour rally that added $190 billion to the crypto market and triggered $2.98 billion in liquidations. Here's what Treasury buybacks, a massive short squeeze, and new SEC rules mean for traders on WEEX.


















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.

